Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.

Saved in:
Bibliographic Details
Title: Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.
Authors: Napolitano A; The Royal Marsden Hospital and The Institute for Cancer Research, London, United Kingdom., Joensuu H; Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Rothschild S; The Life Raft Group, Wayne, New Jersey., Evans D; The Life Raft Group, Wayne, New Jersey., Heinrich MC; Portland VA Health Care System and Oregon Health and Science University, Knight Cancer Institute, Portland., Sutton TL; Oregon Health and Science University, Knight Cancer Institute, Portland., Mayo SC; Oregon Health and Science University, Knight Cancer Institute, Portland., Boye K; Oslo University Hospital, Oslo, Norway., Falkenhorst J; Essen University Hospital, Essen, Germany., Le Cesne A; Gustave Roussy, Villejuif, France., Hohenberger P; University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany., Rutkowski P; Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland., van Houdt WJ; the Netherlands Cancer Institute, Amsterdam, the Netherlands., Steeghs N; the Netherlands Cancer Institute, Amsterdam, the Netherlands., Gelderblom H; Leiden University Medical Center, Leiden, the Netherlands., Desar IME; Radboud University Medical Centre, Nijmegen, the Netherlands., Pantaleo MA; DIMES, University of Bologna, Bologna, Italy., Nishida T; National Cancer Center Hospital East, Kashiwa, Tokyo, and JCHO Osaka Hospital, Osaka, Japan., Reichardt P; HELIOS Clinic Berlin Buch, Berlin, Germany., Blay JY; Center Léon Bérard, Lyon, France., Somaiah N; MD Andersen Cancer Center, University of Texas, Houston., Haddad EFN; MD Andersen Cancer Center, University of Texas, Houston., Grignani G; Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy., Baldi GG; Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy., Steigen SE; University Hospital of Northern Norway and University of Tromsø, Tromsø, Norway., Braconi C; University of Glasgow, Glasgow, United Kingdom., Nilsson B; Sahlgrenska University Hospital, Gothenburg, Sweden., Singh AS; University of California at Los Angeles, Los Angeles., Fumagalli E; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Cananzi FCM; IRCCS Humanitas Research Hospital, Rozzano, Italy.; Humanitas University, Pieve Emanuele, Italy., Italiano A; Institut Bergonié, Bordeaux, France., Ceruso MS; Institut Bergonié, Bordeaux, France., Brunello A; Istituto Oncologico Veneto-IRCCS, Padova, Italy., Magnússon MK; University of Iceland, Reykjavik, Iceland., Jonasson JG; Landspitali University Hospital, Reykjavik, Iceland., Marquina G; Hospital Clínico San Carlos, School of Medicine, Uversidad Complutense de Madrid, Instituto de Investigación Sanitaria, Madrid, Spain., Hindi N; Biomedicine Institute of Seville/Virgen del Rocío University Hospital, Sevilla, Spain., Cirilli C; Modena Cancer Registry, AUSL Modena, Modena, Italy., Federico M; University of Modena and Reggio Emilia, Modena, Italy., Fausti V; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Bordoni A; Ticino Cancer Registry, Institute of Pathology South of Switzerland, Locarno, Switzerland., Sufliarsky J; Comenius University and National Cancer Institute, Bratislava, Slovak Republic., Mazzocca A; Policlinico Universitario Campus Bio-Medico, Rome, Italy., Martin-Broto J; Biomedicine Institute of Seville/Virgen del Rocío University Hospital, Sevilla, Spain., Gronchi A; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Trent JC; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida., Casali PG; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy., Bauer S; Essen University Hospital, Essen, Germany., Jones RL; The Royal Marsden Hospital and The Institute for Cancer Research, London, United Kingdom., Vincenzi B; Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Source: JAMA oncology [JAMA Oncol] 2026 Apr 01; Vol. 12 (4), pp. 407-412.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2374-2445
DOI:10.1001/jamaoncol.2026.0007